187 related articles for article (PubMed ID: 30287928)
1. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
Zhang HX; Chen Y; Xu R; He QY
Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
[TBL] [Abstract][Full Text] [Related]
2. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
3. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
[TBL] [Abstract][Full Text] [Related]
4. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.
Tang X; Wang H; Fan L; Wu X; Xin A; Ren H; Wang XJ
Free Radic Biol Med; 2011 Jun; 50(11):1599-609. PubMed ID: 21402146
[TBL] [Abstract][Full Text] [Related]
5. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
Roh JL; Jang H; Kim EH; Shin D
Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway.
Xia C; Bai X; Hou X; Gou X; Wang Y; Zeng H; Huang M; Jin J
Cell Physiol Biochem; 2015; 37(2):816-24. PubMed ID: 26356271
[TBL] [Abstract][Full Text] [Related]
8. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
9. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor actions of the new antibiotic boningmycin through induction of apoptosis and cellular senescence.
Gao N; Shang B; Zhang X; Shen C; Xu R; Xu H; Chen R; He Q
Anticancer Drugs; 2011 Feb; 22(2):166-75. PubMed ID: 20948431
[TBL] [Abstract][Full Text] [Related]
12. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1.
Furfaro AL; Macay JR; Marengo B; Nitti M; Parodi A; Fenoglio D; Marinari UM; Pronzato MA; Domenicotti C; Traverso N
Free Radic Biol Med; 2012 Jan; 52(2):488-96. PubMed ID: 22142473
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 mediates the protective effects of homocysteine by increasing the levels of GSH content in HepG2 cells.
Zhang B; Dong JL; Chen YL; Liu Y; Huang SS; Zhong XL; Cheng YH; Wang ZG
Mol Med Rep; 2017 Jul; 16(1):597-602. PubMed ID: 28560453
[TBL] [Abstract][Full Text] [Related]
14. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
15. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
[TBL] [Abstract][Full Text] [Related]
17. Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation.
Lee HR; Cho JM; Shin DH; Yong CS; Choi HG; Wakabayashi N; Kwak MK
Mol Cell Biochem; 2008 Nov; 318(1-2):23-31. PubMed ID: 18587629
[TBL] [Abstract][Full Text] [Related]
18. Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.
Zanotto-Filho A; Masamsetti VP; Loranc E; Tonapi SS; Gorthi A; Bernard X; Gonçalves RM; Moreira JC; Chen Y; Bishop AJ
Mol Cancer Ther; 2016 Dec; 15(12):3000-3014. PubMed ID: 27638861
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of boningmycin induced cellular senescence of human tumor cells].
Zhang XM; Gao N; Chen RX; Xu HZ; He QY
Yao Xue Xue Bao; 2010 May; 45(5):589-94. PubMed ID: 20931760
[TBL] [Abstract][Full Text] [Related]
20. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
